Delivery is still key in RNAi
This article was originally published in Scrip
Many companies are actively exploring the potential of RNAi therapeutics, which aim at the "root" cause of genetic disease by silencing specific messenger RNAs and inhibiting the production of disease-causing proteins. But effective delivery of siRNAs into cells remains a major challenge. RNAi drugs by themselves are usually unable to pass through cell membranes and into the cytoplasm where they work.